This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.
A NEW (to the United States at any rate) inactivated poliomyelitis vaccine is likely to become available before the end of the year.
If the new inactivated vaccine is licensed, it will become the primary agent for use in those patients in whom live-virus oral polio vaccine is contraindicated or who prefer to be immunized with the inactivated vaccine, replacing the currently licensed, enhanced inactivated polio vaccine made by Connaught Laboratories Inc, Swiftwater, Pa.
The two vaccines are similar in safety, immunogenicity, and efficacy. Their great advantage is that there is no incidence of vaccine-associated paralysis as occurs in rare instances with the oral live-virus vaccine.
Cultivated on Different Cells
Indeed, the only real difference between the two vaccines is the cells on which the vaccine virus is cultivated. The currently licensed product is grown on human diploid cells; the new agent is grown on VERO cells, a monkey kidney
Marwick C. New Inactivated Polio Vaccine Expected Soon. JAMA. 1990;264(2):166. doi:10.1001/jama.1990.03450020018004